Brean Murray Carret & Co. Maintains a 'Buy' on Halozyme Therapeutics (HALO); Oversold on HyQ News - Opportunity Heading Into Rituxan Phase 3

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. AVGO
7. SPCX
8. OSIS
9. REAX
10. RMAX

April 16, 2012 1:04 PM EDT
Get Alerts HALO Hot Sheet
Price: $108.17 +1.93%

Rating Summary:
    15 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Brean Murray Carret & Co. maintains a 'Buy' on Halozyme Therapeutics (NASDAQ: HALO) price target lowered from $13 to $11.

Analyst, Jonathan Aschoff, said, "Halozyme and Baxter (NYSE: BAX)(Buy) announced today that the FDA is requiring additional informationto complete the BLA for approval of HyQ, which is indicated for primary immunodeficiency...Given that the FDA concerns revolve around the long term chronic use of HyQ, we anticipate a 2 year delay with HyQ."

Aschoff lowers FY12 EPS loss from (0.51) to (0.62) and FY13 from (0.14) to (0.23)

For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.

Shares of Halozyme Therapeutics closed at $11.27 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Brean Murray Carret & Co.